Lenalidomide Treatment Delays Progression From Smoldering to Symptomatic Myeloma
Observation is the standard approach to managing most patients with smoldering multiple myeloma (MM), but results from a phase III study suggest that early...
Early-Phase Trial Suggests Bispecific Antibody CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma
Watch our interview with Luciano J. Costa, MD, PhD.
CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3...
Daratumumab, Carfilzomib, and Dexamethasone Combination Improves PFS in Patients with Relapsed/Refractory Multiple Myeloma
Adding daratumumab to a combination of carfilzomib and dexamethasone (KdD) led to a 37% improvement in progression-free survival (PFS), compared with carfilzomib and dexamethasone...
Post-Induction CVD Chemotherapy Improves PFS in Patients With Newly Diagnosed Myeloma
For patients with newly diagnosed multiple myeloma (MM) who had a suboptimal response to immunomodulatory drug-based induction therapy, intensification treatment with cyclophosphamide, bortezomib, and...
Can These Biomarkers Predict Patients’ Response to Venetoclax?
In an analysis of the phase III BELLINI trial, researchers identified two biomarkers that predict response to venetoclax in patients with relapsed/refractory multiple myeloma...
Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS
Saad Usmani, MD, MBBS, shares findings from the CANDOR trial, in which the three-drug combination reduced the risk of disease progression or death by...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd) alone. However,...
Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma
Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...
Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma
Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and...
FDA Approves Daratumumab-Based Quadruplet Regimen for Transplant-Eligible Myeloma
The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
